MedTrace Logo

Early Dehiscence Markers in Ovarian Cancer Surgery

NCT03131492 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2022-09-29

No results posted yet for this study

Summary

EDMOCS trial pretends to evaluate if C-reactive protein (CRP) and procalcitonin (PCT) can predict intestinal anastomotic leaks before early discharge in advanced ovarian cancer surgery requiring intestinal resection. These markers have already been positively tested in colorectal cancer surgery, but not yet in ovarian surgery.

Patients undergoing intestinal resection in ovarian cancer surgery will be included. C-reactive protein and PCT will be measured pre-operatively, and on the second, fourth and sixth postoperative day. Thirty-day readmissions, re-operations and mortality will be recorded.

Conditions

  • Ovarian Neoplasms Malignant
  • Anastomotic Leak

Interventions

DIAGNOSTIC_TEST

Blood test

C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Antonio Gil-Moreno, MD · Head of Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital

  • Asunción Pérez-Benavente, MD · Head of Unit of Gynecology Oncology Department of Obstetrics and Gynecology

  • José Luis Sánchez-Iglesias, MD · Department of Obstetrics and Gynecology

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2020-12-31
Completion
2021-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131492 on ClinicalTrials.gov